FG-4592: Phase IIb data

An open-label Phase IIb trial in 96 patients with stage 3/4 CKD who were not on dialysis showed that thrice-weekly oral FG-4592 led to an increase in hemoglobin of

Read the full 290 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE